Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) EBITDA (2016 - 2025)

Historic EBITDA for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $16.8 million.

  • Macrogenics' EBITDA fell 7012.44% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.9 million, marking a year-over-year increase of 2221.32%. This contributed to the annual value of -$67.0 million for FY2024, which is 63911.03% down from last year.
  • According to the latest figures from Q3 2025, Macrogenics' EBITDA is $16.8 million, which was down 7012.44% from -$36.3 million recorded in Q2 2025.
  • Macrogenics' EBITDA's 5-year high stood at $57.4 million during Q2 2023, with a 5-year trough of -$66.7 million in Q1 2022.
  • Over the past 5 years, Macrogenics' median EBITDA value was -$39.9 million (recorded in 2021), while the average stood at -$24.1 million.
  • Per our database at Business Quant, Macrogenics' EBITDA plummeted by 267099.24% in 2021 and then skyrocketed by 23879.85% in 2023.
  • Macrogenics' EBITDA (Quarter) stood at -$58.1 million in 2021, then surged by 122.23% to $12.9 million in 2022, then plummeted by 456.65% to -$46.0 million in 2023, then soared by 66.49% to -$15.4 million in 2024, then soared by 209.09% to $16.8 million in 2025.
  • Its EBITDA stands at $16.8 million for Q3 2025, versus -$36.3 million for Q2 2025 and -$41.0 million for Q1 2025.